Objective: To determine the effects of the GOLO weight management program with Release supplement versus placebo on weight and metabolic parameters in subjects with obesity.
Introduction
Obesity is a common metabolic disorder in the United States and major risk factor for diabetes, cardiovascular disease and cancer [1, 2] . To treat obesity, clinical guidelines recommend lifestyle modifications including reductions in daily caloric intake and increase in exercise as first line treatment [3] . Recommendations for second line treatment include pharmacotherapy or even bariatric surgery, but each comes with potential side effects and significant risk [4, 5] .
People that are overweight and obese exhibit a heterogeneity in glucose metabolism, ranging from normal to insulin resistant to type 2 diabetes [6] . Elevated body weight and BMI are significant risk factors for the development of insulin resistance and type 2 diabetes mellitus [7] . People who are overweight and obese on this spectrum often have difficulty obtaining meaningful or sustained weight loss [8] . However, people with obesity who are insulin resistant or diabetic who lose weight generally improve glucose, insulin and lipid metabolism [9] .
Commercial outpatient programs that encourage healthy dieting and exercise are commonly used by patients seeking weight loss in the US [10] . However, long term success of these programs can vary and has been lightly studied by the medical community [10, 11] . In addition, over-the-counter supplements are often used by patients with obesity, although clinical study data supporting their use is often inconclusive or lacking [12, 13] .
The GOLO Weight Management Program (GWMP) is a commercially available program that includes a diet and exercise plan in addition to a supplement known as Release (www.golo.com). The GWMP is designed to help people who are overweight or obese obtain a balance of nutrients from conventional foods, eat defined portioned meals leading to gradual weight loss and participate in a low-moderate level of daily exercise. The GWMP diet is a point-based system that includes foods from all four of the macronutrient food groups. Daily total caloric intake is based on the individual's sex, age, weight size and activity level. Additionally, the program includes printed instructions, motivation and tips supporting compliance and recommends a minimum of 15 minutes of exercise per day.
The Release supplement contains 7 plant-based ingredients and 3 minerals ( Figure 1 ). Scientific evidence suggests that chromium, zinc and Banaba leaf extract supplements may have positive effects on glycemic control, lipid metabolism and healthy weight management [14] [15] [16] .
Banaba leaf (Lagerstromia speciose) is a traditional medicine from southeast Asia which has shown hypoglycemic effects through unknown mechanisms [16] [17] [18] . Zinc is an essential trace mineral that plays an important role in normal islet function and is used in the production of insulin. One mechanism by which zinc may work to control glucose is through supporting insulin signal transduction, which may not function optimally in those with increased visceral fat [15] . Chromium has been shown to be an important cofactor in the action of insulin [19] . These agents are included in many supplements sold to people with obesity and diabetes. However, more rigorous studies of the effects of nutritional supplements on these conditions are needed, and this serves as an impetus for the current study.
In unpublished case studies of clinical and wellness program use in South Africa and the US, GWMP with Release supplement was shown to reduce body weight in both healthy and diabetic people who were overweight or obese [20] . Secondary endpoints including measures of blood sugar control and lipid metabolism were observed to improve in subjects participating in the study [20] .
An open-label pilot study evaluating the effect of the GWMP with Release supplement on weight and indicators of glycemic control in subjects with stable type 2 diabetes mellitus and obesity was conducted at our site in 2017 [21] . This study demonstrated weight loss of -3.3 kg (SD 2.47; p < 0.001) which represented an average of -3.53% (SD 0.02) weight loss and was statistically significant over a 13-week treatment period. In addition, reductions in Hemoglobin A1C averaged -0.61% (0.86; p = 0.01) and reductions in HOMA-IR, a measure of insulin resistance, averaged -2.25 (3.33; p = 0.02) which were both statistically significant. These findings served as a scientific basis for a larger randomized placebo study.
While the GWMP has been developed and used in both healthy people and people with type 2 diabetes, more research is needed to determine to what extent the program and supplement support healthy weight loss. In addition, the component of weight loss and metabolic improvement contributed to by Release supplement is not known. This randomized, double-blind placebo-controlled study was intended to measure the effects of the GWMP with Release supplement versus GWMP with placebo supplement in a representative group of obese subjects with or without diabetes at one outpatient medical practice.
Methods
In this randomized, double-blind placebo-controlled study we randomized obese subjects with ages between 18 to 80 years and BMI between 30 and 60 kg/m 2 to the GWMP with either Release supplement or placebo. The study was conducted from July 2018 until December 2018. The site Buynak Clinical Research in Valparaiso, IN recruited subjects from the practice's patient population or through social media advertisement.
Subjects with and without type 2 diabetes were included, but those with type 1 diabetes or on insulin treatment were excluded. Other exclusion criteria included history of surgical treatments for weight loss or any unstable medical condition. All subjects provided informed consent in the form of a written consent form. The study was approved by Western Institutional Review Board. The study consisted of 8 visits over approximately 13 weeks.
At visit 1, study eligibility was determined, and subjects were given the commercially available GOLO Weight Management Program and instructed on the program's diet and exercise guidelines. Subjects were randomized in a 1:1 fashion to receive either the Release supplement or matching placebo and instructed to take one capsule three times a day with meals. Subjects and study staff were blinded to the treatment allocation, and Release supplement and matching placebo capsules were supplied in blinded containers. Placebo capsule contained maltodextrin. At each in-office visit, unused Release supplement tablets and placebo were collected, compliance was calculated by pill counting, and open labeled 90-count Release supplement bottles were dispensed as needed.
Laboratory and body measurements were obtained as outlined below. Visit 2 consisted of a telephone call to subjects to assess tolerability of the program. At approximately 2-week intervals, subjects returned for an office visit for compliance and tolerability assessment and body measurements. The final visit 8 occurred at approximately week 13 and included body measurements, laboratory analysis and compliance and tolerability assessment.
Body measurements were completed at in-office visits 1, 3 and 4 and included fasting weight, height, waist and hip circumference, and resting blood pressure and pulse. A Tanita bioimpedance scale (MC-780U) was used to measure weight and calculate BMI, body fat and visceral fat. Laboratory evaluations were completed at Visit 1 and Visit 8 which included hemoglobin A1C, fasting insulin, fasting blood glucose and lipid panel (total cholesterol, LDL, HDL, triglycerides). A metabolic panel was also completed at Visit 1 and Visit 8 that included sodium, potassium, chloride, BUN, creatinine, calcium, total protein, albumin, alkaline phosphate, AST, ALT and carbon dioxide. Homeostatic model assessment of insulin resistance HOMA-IR was calculated using the formula [fasting blood glucose(mg/dl) × fasting insulin (uIU/ml)/405] [22] and was completed for subjects at the beginning and end of the 13-week treatment period.
The primary endpoint for the study was change in weight at the end of approximately 13 weeks of treatment with GWMP with Release supplement versus GWMP with placebo. Secondary endpoints included differences in body measurements and body composition analysis, vital signs, A1C, fasting blood glucose, fasting insulin levels and HOMA-IR at the end of 13 weeks of treatment between the two treatment groups. Additional secondary endpoints included changes in lipid panel and metabolic panel results at the end of the study between the groups. Additional safety evaluations included the tracking of adverse events throughout the study period.
Differences between the treatment and control groups were analyzed using two-tailed t-tests assuming unequal variances at a significance level of 0.05. These tests were used to compare the change of each group over the 13-week trial and to assess randomization of the subjects.
GOLO weight management program
At visit 1 subjects were educated on the GWMP diet and exercise plan and were given the same supplemental information given to GOLO commercial customers. Subjects were instructed to select at least one serving from each of 4 food groups (protein, vegetables, carbohydrates and fats) at each of the three meals. Protein or proteincarbohydrate snacks were permitted within the subject's daily calorie allotment. Examples of possible serving choices were outlined in the GOLO literature.
The total amount of food that the subject consumed per day was based on the subject's basal metabolic rate and exercise activity. Basal metabolic rates were derived at enrollment through a predetermined conversion based on sex, age, waist size and activity level. Subjects were instructed to add additional calorie allowances based on additional exercise as outlined in the GOLO literature. Daily calorie goals represented an approximately 500 calorie reduction from baseline maintenance levels. Compliance to diet was tracked through subject daily food diaries and subjects' calorie calculations that were later verified by study staff. Exercise was tracked in 15-minute increments in a subject diary.
Results
Sixty-eight subjects were consented and randomized into the study. Average baseline characteristics of the subjects are contained in table 1. The average baseline weight was 106.97 kg (SD 16.64) and the average BMI was 38.82 kg/m 2 (6.15) which is considered obese.
Among the initial study population, average hemoglobin A1C (5.72%, SD 0.84), fasting blood glucose (104.8 mg/dl, SD 27.9), LDL cholesterol (105.24 mg/dl, SD 22.85) and initial resting blood pressure (124.99 mmHg/79.34 mmHg, SD 13.37/10.03) were slightly elevated. This reflected the mixed nature of the group which contained both diabetic subjects and non-diabetic subjects and the heterogeneity of pre-treatment with anti-diabetic, blood pressure and cholesterol medications. While the average fasting insulin level [11.4 uIU/ml (5.910; normal 1.9-23.0 uIU/ml] was within normal limits the average HOMA-IR [3.06 (1.90), normal 0.5-1.9] indicated the presence of insulin resistance in this subject population. Table 2 describes the comparison of baseline characteristics between the placebo and treatment groups. Generally, baseline differences were minor and not statistically significant. However, baseline diastolic blood pressure and pulse were higher in the treatment group at baseline than the placebo group, a difference that reached statistical significance. 34 subjects completed the approximately 13-week study period. Of those subjects, 16 subjects randomized to placebo (Group A) and 18 subjects randomized to Release supplement (Group B). Of that total, 5 subjects had been previously diagnosed with type 2 diabetes and were on oral anti-diabetic therapy. Of the 68 subjects screened, 20 subjects self-terminated early for personal reasons (lack of time to participate, travel, personal emergencies), 11 subjects were removed early for poor compliance with diet or pill counts and 3 subjects withdrew for adverse events (2 loose stool, 1 nausea).
Changes from baseline week 1 to week 13 in weight, BMI, body analysis and body measurements for each group are listed in table 3. In terms of the primary endpoint, subjects randomized to the Release supplement lost statistically significant more weight than those assigned to placebo [placebo -3.38 kg (2.81); treatment -6.07 kg (4.63); p = 0.047]. This represented a -3% change in weight (95%CI: -2 to -5) in the placebo group compared to a -6% change in weight (95%CI" -3 to -8) in the treatment group. In addition, reductions in waist circumference [placebo -2.37 cm (5.12); treatment -7.26 cm (6.43); p = 0.019] and waist/height ratio [placebo -0.01 (0.03); treatment -0.04 (0.04); p = 0.026] were also statistically significant for the Release-treated group compared to placebo. In terms of vital signs, subjects randomized to the Release supplement showed statistically significant greater reductions in diastolic BP [placebo 1.31 mmHg (7.38); treatment -4.11 mmHg (6.62); p = 0.032] and pulse [placebo 4.38 bpm (10.44); treatment -3.44 bpm (4.83); p = 0.012].
Changes from baseline week 1 to week 13 in markers of glycemic control and insulin sensitivity are listed in table 4. Levels of fasting blood glucose [placebo 0.73 mg/dl (10.71); treatment -10.71 mg/ dl (28.61); p = 0.178] and hemoglobin A1C [placebo 0.02% (0.18); treatment -0.18 (0.53); p = 0.202] demonstrated a trend towards larger (13.18) ; p = 0.642] demonstrated a trend towards larger reductions in subjects randomized to the Release supplement compared to placebo but were not statistically significant. However, statistically significant larger improvements in triglyceride levels [placebo 19.47 mg/dl (28.04); treatment -35.21mg/ dl (43.29); p < 0.001] were seen in subjects randomized to the Releasetreated group compared to placebo. Changes in liver enzymes and kidney functions were not different between the two groups ( Table 5 ).
Measure Placebo Baseline (SD) Group A Treatment Baseline (SD) Group B Average Difference (T -P) P Value
Weight ( 
Discussion
This study demonstrated statistically significant improvements in several important body measurements and laboratory tests in subjects following the GWMP who were randomized to the Release supplement compared to placebo. Because all subjects followed a similar diet and exercise plan, these results suggest that the components of Release supplement may add significant health benefits to the GWMP.
Patients with obesity often to struggle to lose weight even when following proper diet and exercise program [8] . In this study, the GWMP alone produced weight loss in the control and treatment groups. However, the addition of Release supplement resulted in a statistically significant larger weight loss [placebo -3.38 kg (2.81); treatment -6.07 kg (4.63); p = 0.047] compared to placebo. By achieving this primary endpoint, this study indicates that the Release supplement could serve as a useful addition to diet and exercise programs for patients with type 2 diabetes.
In addition to weight loss, treatment programs that target additional risk factors for metabolic syndrome and cardiovascular disease like elevated blood pressure, central obesity and abnormal lipid metabolism are also needed to improve health in patients with obesity [1] . Each of these factors contribute additional cardiovascular risk in addition to that of diabetes and obesity alone [23] . The statistically significant improvements in waist circumference, diastolic BP and triglycerides levels demonstrated in subjects randomized to the Release supplement compared to placebo in this study indicate additional potential health benefits for participants following the GWMP. In addition to these statistically significant improvements, positive trends were seen in reductions of that were not statistically significant. Combined with weight loss, all of these additional benefits could substantially improve the cardiovascular risk profile in patients participating in the GWMP with Release supplement. Improvements in markers of insulin resistance were the most notable results of the study and are consistent with results from the previous pilot study of the GWMP with Release supplement [21] . This study demonstrated a significant improvement in insulin resistance as measured by fasting insulin levels and HOMA-IR in the subjects treated with the GWMP with Release supplement for 13-weeks as compared to placebo supplement. Elevated levels of fasting insulin and HOMA-IR are hallmarks of the metabolic syndrome and type 2 diabetes, and elevated HOMA-IR serves as another important independent risk factor for cardiovascular disease [24, 25] .
In the current study, reductions in HOMA-IR of -27 % (95% CI: -47 to -8) in subjects randomized to the Release supplement approximate that seen with even prescribed medications like pioglitazone or metformin [26] . In that comparable study, pioglitazone reduced HOMA-IR by 39% which was statically significant, while metformin reduced HOMA-IR by 25% and was not statistically significant [26] .
Another study in a group of insulin resistant people demonstrated that pioglitazone reduced HOMA-IR by -24% after a year of treatment (from 5.4 ± 2.6 to 4.1 ± 2.8, p < 0.0001) which was statistically significant [27] .
The components of the GWMP that are responsible for the improvement in HOMA-IR have not been clearly identified. Weight loss itself can lower HOMA-IR levels, although not to the extent seen in this study [28] . This study indicates the components of the Release supplement may play a role in reducing insulin resistance and are possibly additive to that achieved by diet alone.
The significant improvements in HOMA-IR demonstrated by the GWMP system with the Release supplement suggest a beneficial role in other disease states including the Metabolic Syndrome or PCOS. In these disorders, insulin resistance is generally a major component, and treatment of the insulin resistance improves clinical outcomes [29, 30] . More studies are needed of the GWMP with Release in these individual areas of interest.
The study was limited by selection of subjects at only one clinical site. Baseline differences between groups, especially those that were statistically significant, could have confounded the magnitude of results. The large number of dropouts could also have confounded the results. As in any diet study, subject compliance with diet and exercise was difficult to measure and poor subject compliance with the GWMP diet, based on food logs, or exercise component may also have influenced the results of the study. Although compliance with the Release supplement as obtained by pill counts (95 percent overall compliance by pill count) was excellent, compliance with diet and exercise recommendations was self-reported, variable and more difficult to quantify.
Conclusion
Treatment with the GOLO Weight Management Program with Release supplement compared to placebo for 13-weeks resulted in statistically significant greater weight loss and improvement in metabolic parameters including insulin resistance in patients with obesity.
